NBRV vs. ACRV, PRQR, ACTU, ACRS, IKT, SCPH, LYEL, ALEC, IPHA, and GLSI
Should you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Acrivon Therapeutics (ACRV), ProQR Therapeutics (PRQR), Actuate Therapeutics (ACTU), Aclaris Therapeutics (ACRS), Inhibikase Therapeutics (IKT), scPharmaceuticals (SCPH), Lyell Immunopharma (LYEL), Alector (ALEC), Innate Pharma (IPHA), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry.
Nabriva Therapeutics vs.
Nabriva Therapeutics (NASDAQ:NBRV) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Acrivon Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Acrivon Therapeutics' return on equity of -47.95% beat Nabriva Therapeutics' return on equity.
Nabriva Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Acrivon Therapeutics had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 1 mentions for Nabriva Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.99 beat Nabriva Therapeutics' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.
Acrivon Therapeutics has a consensus target price of $23.67, indicating a potential upside of 327.20%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Nabriva Therapeutics.
Nabriva Therapeutics received 358 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 97.22% of users gave Acrivon Therapeutics an outperform vote while only 55.35% of users gave Nabriva Therapeutics an outperform vote.
Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Summary
Acrivon Therapeutics beats Nabriva Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Nabriva Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nabriva Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NBRV) was last updated on 2/22/2025 by MarketBeat.com Staff
Free NBRV Stock Alerts